Success Metrics

Clinical Success Rate
66.7%

Based on 6 completed trials

Completion Rate
67%(6/9)
Active Trials
2(13%)
Results Posted
0%(0 trials)
Terminated
3(19%)

Phase Distribution

Ph not_applicable
6
38%
Ph phase_1
1
6%
Ph phase_2
3
19%
Ph phase_3
3
19%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
3(23.1%)
Phase 3Large-scale testing
3(23.1%)
N/ANon-phased studies
6(46.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

54.5%

6 of 11 finished

Non-Completion Rate

45.5%

5 ended early

Currently Active

2

trials recruiting

Total Trials

16

all time

Status Distribution
Active(3)
Completed(6)
Terminated(5)
Other(2)

Detailed Status

Completed6
Terminated3
Withdrawn2
Recruiting2
unknown2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
2
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (7.7%)
Phase 23 (23.1%)
Phase 33 (23.1%)
N/A6 (46.2%)

Trials by Status

withdrawn213%
completed638%
enrolling_by_invitation16%
recruiting213%
terminated319%
unknown213%

Recent Activity

2 active trials
Showing 5 of 16
recruitingphase_3

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

NCT06122584
withdrawnphase_1

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

NCT06881823
recruitingphase_3

18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028

NCT05520255
completedphase_3

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

NCT04742361
completednot_applicable

Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer

NCT05534594
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT06122584Phase 3

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Recruiting
NCT06881823Phase 1

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

Withdrawn
NCT05520255Phase 3

18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028

Recruiting
NCT04742361Phase 3

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

Completed
NCT05534594Not Applicable

Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer

Completed
NCT05712174Phase 2

A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer

Terminated
NCT05815316Phase 2

18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer

Withdrawn
NCT05123300Not Applicable

PRISMA-PET - Primary Staging of Prostate Cancer With PSMA

Terminated
NCT06723665Not Applicable

The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients

Enrolling By Invitation
NCT05709535

PSMA-PET/CT Registry

Terminated
NCT05079828Not Applicable

Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007

Completed
NCT04733768Phase 2

18F-PSMA-1007 PET/CT Imaging in Patients with Biochemically Recurrent or High-risk Prostate Cancer

Completed
NCT04986280

Diagnostic Accuracy and Performance of 18F-PSMA-1007

Completed
NCT05422105

Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient

Unknown
NCT05448404Not Applicable

A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma

Unknown
NCT03187990Not Applicable

Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16